Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance vinflunine after gemcitabine + cisplatin in advanced urothelial carcinoma
2011-000272-34Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vinflunine in transitional cell carcinoma (TCC), sponsored by Pierre Fabre Laboratories. Primary endpoint: Progression-free survival rate at 3 months. Started Jun 2011; status: completed.
02
Drugs
vinflunine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2011-000272-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000272-34.